Magnetic resonance imaging features influencing high-intensity focused ultrasound ablation of adenomyosis with a nonperfused volume ratio of ≥90% as a measure of clinical treatment success: retrospective multivariate analysis

References

• Bergholt T, Eriksen L, Berendt N, et al. Prevalence and risk factors of adenomyosis at hysterectomy. Hum Reprod. 2001;16:2418–2421.
   PubMed Web of Science ®Google Scholar
• Kepkep K, Tuncay YA, Goynumer G, et al. Transvaginal sonography in the diagnosis of adenomyosis: which findings are most accurate? Ultrasound Obstet Gynecol. 2007;30:341–345.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Dorta M, et al. Transvaginal ultrasonography in the diagnosis of diffuse adenomyosis. Fertil Steril. 1992;58:94–97.
   PubMed Web of Science ®Google Scholar
• Atzori E, Tronci C, Sionis L. Transvaginal ultrasound in the diagnosis of diffuse adenomyosis. Gynecol Obstet Invest. 1996;42:39–41.
   PubMed Web of Science ®Google Scholar
• Fukunishi H, Funaki K, Sawada K, et al. Early results of magnetic resonance guided focused ultrasound surgery of adenomyosis: analysis of 20 cases. J Minim Invasive Gynecol. 2008;15:571–579.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang Y, Tang J. Safety and efficacy of high intensity focused ultrasound ablation therapy for adenomyosis. Acad Radiol. 2009;16:1416–1423.
   PubMed Web of Science ®Google Scholar
• Zhou M, Chen JY, Tang LD, et al. Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center. Fertil Steril. 2011;95:900–905.
   PubMed Web of Science ®Google Scholar
• Kim KA, Yoon SW, Lee C, et al. Short-term results of magnetic resonance imaging-guided focused ultrasound surgery for patients with adenomyosis: symptomatic relief and pain reduction. Fertil Steril. 2011;95:1152–1155.
   PubMed Web of Science ®Google Scholar
• Fan TY, Zhang L, Chen W, et al. Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis. Eur J Radiol. 2012;81:3624–3630.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li K, Xie B, et al. Effective ablation therapy of adenomyosis with ultrasound-guided high-intensity focused ultrasound. Int J Gynaecol Obstet. 2014;124:207–211.
   PubMed Web of Science ®Google Scholar
• Lee JS, Hong GY, Park BJ, et al. Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid and adenomyosis: a single center experience from the Republic of Korea. Ultrason Sonochem. 2015;27:682–687.
   PubMed Web of Science ®Google Scholar
• Shui L, Mao S, Wu Q, et al. High-intensity focused ultrasound (HIFU) for adenomyosis: two-year follow-up results. Ultrason Sonochem. 2015;27:677–681.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang W, Wang Y, et al. Clinical predictors of long-term success in ultrasound guided high-intensity focused ultrasound ablation treatment for adenomyosis: a retrospective study. Medicine. 2016;95:e2443.
   PubMed Web of Science ®Google Scholar
• Gong C, Yang B, Shi Y, et al. Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: a retrospective study. Int J Hyperthermia. 2016;32:496–503.
   PubMed Web of Science ®Google Scholar
• Ferrari F, Arrigoni F, Miccoli A, et al. Effectiveness of Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) in the uterine adenomyosis treatment: technical approach and MRI evaluation. Radiol Med. 2016;121:153–161.
   PubMed Web of Science ®Google Scholar
• Gong C, Setzen R, Liu Z, et al. High intensity focused ultrasound treatment of adenomyosis: the relationship between the features of magnetic resonance imaging on T2 weighted images and the therapeutic efficacy. Eur J Radiol. 2017;89:117–122.
   PubMed Web of Science ®Google Scholar
• Keserci B, Duc NM. The role of T1 perfusion-based classification in predicting the outcome of magnetic resonance-guided high-intensity focused ultrasound treatment of adenomyosis. Int J Hyperthermia. 2018;34:306–314.
   PubMed Web of Science ®Google Scholar
• FDA approves label change for non-invasive fibroid treatment. April 7, 2009. InSightec Ltd. Available at: https://www.insightec.com/us/news-events/press-releases/fda-approves-label-change-for-non-invasive-fibroid-treatment. [Cited 21 June, 2018].
   Google Scholar
• Sacks D, McClenny TE, Cardella JF, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14:S199–S202.
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103:e9–17.
   PubMed Web of Science ®Google Scholar
• Spies JB, Coyne K, Guaou N, et al. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002;99:290–300.
   PubMed Web of Science ®Google Scholar
• Bewick V, Cheek L, Ball J. Statistics review 14: logistic regression. Crit Care. 2005; 9:112–118.
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–35.
   PubMed Web of Science ®Google Scholar
• O’Brien RM. A Caution regarding rules of thumb for variance inflation factors. Qual Quant. 2007;41:673–690.
   Web of Science ®Google Scholar
• Kwack JY, Kwon YS. Laparoscopic surgery for focal adenomyosis. JSLS. 2017;21:e2017.00014.
   PubMed Web of Science ®Google Scholar
• Huang X, Huang Q, Chen S, et al. Efficacy of laparoscopic adenomyomectomy using double-flap method for diffuse uterine adenomyosis. BMC Womens Health. 2015;15:24.
   PubMed Web of Science ®Google Scholar
• Mikami K, Murakami T, Okada A, et al. Magnetic resonance imaging-guided focused ultrasound ablation of uterine fibroids: early clinical experience. Radiat Med. 2008;26:198–205.
   PubMedGoogle Scholar
• Chen L, ter Haar G, Hill CR. Influence of ablated tissue on the formation of high-intensity focused ultrasound lesions. Ultrasound Med Biol. 1997;23:921–931.
   PubMed Web of Science ®Google Scholar
• Ascher SM, Arnold LL, Patt RH, et al. Adenomyosis: prospective comparison of MR imaging and transvaginal sonography. Radiol. 1994;190:803–806.
   PubMed Web of Science ®Google Scholar
• Kim MD, Kim YM, Kim HC, et al. Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes. J Vasc Interv Radiol. 2011;22:497–502.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lim HK, Kim JH, et al. Dynamic contrast-enhanced magnetic resonance Imaging predicts immediate therapeutic response of magnetic resonance-guided high-intensity focused ultrasound ablation of symptomatic uterine fibroids. Invest Radiol. 2011;46:639–647.
   PubMed Web of Science ®Google Scholar
• Zhao WP, Chen JY, Chen WZ. Effect of biological characteristics of different types of uterine fibroids, as assessed with T2-weighted magnetic resonance imaging, on ultrasound-guided high intensity focused ultrasound ablation. Ultrasound Med Biol. 2015;41:423–431.
   PubMed Web of Science ®Google Scholar
• Keserci B, Duc NM. The role of T1 perfusion-based classification in magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids. Eur Radiol. 2017;27:5299–5308.
   PubMed Web of Science ®Google Scholar
• Pennes HH. Analysis of tissue and arterial blood temperatures in the resting human forearm. J Appl Physiol. 1948;1:93–122.
   PubMed Web of Science ®Google Scholar
• Kim YS, Lim HK, Park MJ, et al. Screening magnetic resonance imaging–based prediction model for assessing immediate therapeutic response to magnetic resonance imaging–guided high-intensity focused ultrasound ablation of uterine fibroids. Invest Radiol. 2016;51:15–24.
   PubMed Web of Science ®Google Scholar
• Cheung VY, Lam TP, Jenkins CR, et al. Ovarian reserve after ultrasound-guided high-intensity focused ultrasound for uterine fibroids: preliminary experience. J Obstet Gynaecol Can. 2016;38:357–361.
   PubMed Web of Science ®Google Scholar
• Lee JS, Hong GY, Lee KH, et al. Changes in anti-müllerian hormone levels as a biomarker for ovarian reserve after ultrasound-guided high-intensity focused ultrasound treatment of adenomyosis and uterine fibroid. BJOG: Int J Obstet Gy. 2017;124:18–22.
   PubMed Web of Science ®Google Scholar
• Keserci B, Duc NM. Magnetic resonance imaging parameters in predicting the treatment outcome of high-intensity focused ultrasound ablation of uterine fibroids with an immediate nonperfused volume ratio of at least 90%. Acad Radiol. 2018; DOI: 10.1016/j.acra.2018.01.022.
   PubMed Web of Science ®Google Scholar